Authors: Theodora Manolakou, Dionysis Nikolopoulos, Dimitrios Gkikas, Anastasia Filia, Martina Samiotaki, George Stamatakis, Antonis Fanouriakis, Panagiotis Politis, Aggelos Banos, Themis Alissafi, Panayotis Verginis, Dimitrios T. Boumpas
Published: 2022-10-28
Source: Full article
B cells orchestrate autoimmune responses in patients with systemic lupus erythematosus (SLE), but broad-based B cell–directed therapies show only modest efficacy while blunting humoral immune responses to vaccines and inducing immunosuppression. Development of more effective therapies targeting pathogenic clones is a currently unmet need. Here, we demonstrate enhanced activation of the ATR/Chk1 pathway of the DNA damage response (DDR) in B cells of patients with active SLE disease. Treatment of B cells with type I IFN, a key driver of immunity in SLE, induced expression of ATR via binding of interferon regulatory factor 1 to its gene promoter. Pharmacologic targeting of ATR in B cells, via a specific inhibitor (VE-822), attenuated their immunogenic profile, including proinflammatory cytokine secretion, plasmablast formation, and antibody production. Together, these findings identify the ATR-mediated DDR axis as the orchestrator of the type I IFN–mediated B cell responses in SLE and as a potential novel therapeutic target.